MIDWEST SPECIALTY AUTO PARTS MANUFACTURER

MIDWEST SPECIALTY AUTO PARTS MANUFACTURER

MIDWEST SPECIALTY AUTO PARTS MANUFACTURER

PROJECT #: NVC2222

Revenue: $2.4M | Adjusted EBITDA: $375K
EBITDA Margin: 16%
 
 

About the Company

This Midwest-based Company manufactures and sells high-quality, affordable after-market specialty automotive components for high-performance street and race cars. Its 100% U.S.-made productscustomized for use with dozens of different vehicles and engines, are sold through a large, established base of wholesalers and dealers. It has generated intense customer loyalty and tremendous sales through its knowledgeable staff, growing social media presence, responsive customer service, and industry-leading warrantyA buyer who understands the auto industry and marketing, can manage people and deal with a wide range of customers would find this Company an excellent acquisition opportunity. Its established name, reputation, staff, systems and processes are in place to provide a smooth ownership transition.  

GROWTH OPPORTUNITIES

  • Channel expansion through national retailers,
    e-commerce and wholesale partners
  • Pipeline of new components and product
    development
  • Existing infrastructure and manufacturing
    processes provide for a scalable base and

INVESTMENT HIGHLIGHTS 

• Diverse product portfolio engineered for compatibility with all major
US Automakers
• Products are priced 30%-40% below competing brands while
maintaining superior quality and performance
• Proven quality and reputation allows it to offer an industry-best
warranty

REVENUE AND EBITDA

FISCAL YEAR REVENUE EBITDA EBITDA %
2023 $1.7M  $(136)K  
2024 $2.4M $123K 5.1%
2025 $2.4M $376K 15.6%

INTERESTED?

If this opportunity fits your Company, please fill out the below NDA to get started and contacted with more information.

 

Contact us for more information!

NuVescor Group

(616) 288-4047 Ext: 100

U.S. ORTHOPEDIC DEVICE DEVELOPER AND SELLER

U.S. ORTHOPEDIC DEVICE DEVELOPER AND SELLER

U.S. ORTHOPEDIC DEVICE DEVELOPER AND SELLER

PROJECT #: NVC2270

 
 

About the Company

ExoToe, a U.S.-based Company, developed, obtained federal clearance, commercialized and sells an implant device for surgical use throughout the U.S. The product has been clinically tested, safe and effective alternative to existing surgical interventions. The implant received FDA clearance just before the COVID pandemic, which slowed the Company’s momentum. The device was developed by Drs. Jordan Grossman, Michael Lee, and Shannon Rush, three of the most well-known and respected opinion leaders in foot and ankle surgery. The objective has always been to de-risk the implant for a future owner and not grow the Company. With its evidence-based technology and safe track record, the Company presents a growth opportunity for a new owner.

GROWTH OPPORTUNITIES

Increased sales emphasis – The goal was to de-risk, show efficacy and sell to an orthopedic company, not to grow into a standalone business. There is a limited sales team and business is generated through word of mouth or write-ups in medical journals presenting a significant opportunity for growth for a new owner. 

Repeat business – The implant has an impressive track record, but little effort has been made to build relationships with surgeons who have successfully employed it. 

Scalable Manufacturing – The current manufacturer of record possesses all necessary ISO certifications and offers the scalability required to meet market demands. 

Platform Technology – The implant’s current application is for toes but could easily be adapted to hand and other upper extremities. 

INVESTMENT HIGHLIGHTS 

Intellectual property – The Company has valuable intellectual property for crimping of fixation for foot bone fractures and fusions. 

High success rate – The device has been in the market long enough to show that it works, is safe and effective minimizing risk for a new owner. An independent publication in a peer-review journal demonstrated a best in class fusion rates. 

Patient, surgeon satisfaction – The implant’s success rate and ease of use have won over many doctors and patients. 

Another option – The implants provide an alternative to other types of devices which have had mixed success.  It is also the revisional implant of choice when primary procedures fail. 

Partners in place – The Company has established relationships with capable outside vendors for manufacturing and logistics. It also has a complete DHF (Design History File) and QMS (Quality Management System). 

Additional complementary device – The Company is in the process of FDA clearance for a complementary device in the same space creating an additional opportunity for new owners to generate revenue. 

Cumulative Devices Implanted – Well over 2,000 

 

REVENUE AND EBITDA

Market Opportunity  Sales Team Projection 
Total annual implant revisions: 30,000 Total sales reps: 200 
Target market share: 30%  Sales per rep per week: 1 unit 
Estimated units: 9,000  Selling weeks per year: 50 (assuming 2 weeks off) 
Revenue per unit: $1,000–$1,200  Total units sold: 200 reps × 1 unit/week × 50 weeks = 10,000 units 
Total potential revenue: $9M–$11M  Projected revenue: $10M–$12M 

 

INTERESTED?

If this opportunity fits your Company, please fill out the below NDA to get started and contacted with more information.

 

Contact us for more information!

NuVescor Group

(616) 288-4047 Ext: 100

U.S. ORTHOPEDIC DEVICE DEVELOPER AND SELLER

MIDWEST MEDICAL DEVICE MANUFACTURING COMPANY

MIDWEST MEDICAL DEVICE MANUFACTURING COMPANY

PROJECT #: NVC2265

Revenue: $14,300,000
EBIDTA: $4,100,000
 

About the Company

This Midwest Medical Device Manufacturing Company specializes in ultrasonic wound therapy systems and medical devices. The focus is on medical and surgical instruments, particularly for wound care, with additional product lines pending FDA clearance. Based in the Midwest with global reach, the company generates significant revenue with a low number of employees. Primary services include the design and manufacture of ultrasonic wound therapy systems and the development of medical devices for wound care. Key capabilities include expertise in ultrasonic technology for medical applications, ongoing research and development for new product lines, and compliance with regulatory standards. 

GROWTH OPPORTUNITIES

Expansion into New Markets – There is significant potential to expand into emerging markets where the prevalence of chronic wounds is increasing in regions with aging populations. 

Technological Innovations – Continued investment in research and development can lead to the creation of more advanced and effective wound care solutions.  

INVESTMENT HIGHLIGHTS 

Growing Market Demand – The global market for wound care devices is expanding, driven by the increasing prevalence of chronic wounds and the aging population.  

Market Focus – The Company’s device is primarily used for treating chronic and complex wounds, such as diabetic ulcers, pressure sores, venous ulcers, burn treatments and surgical wounds. 

Value Focused – The Company’s mission and values focus on patient solutions, improving quality care by fostering technology and creativity to anticipate emerging needs. 

REVENUE AND EBITDA

  2023 Actual  2024 Actual  2025 Forecast 
Revenue  $1,450,000  $11,340,000  $14,740,000 
EBITDA  -$170,000  $3,500,000  $4,700,000 

INTERESTED?

If this opportunity fits your Company, please fill out the below NDA to get started and contacted with more information.

 

Contact us for more information!

NuVescor Group

(616) 288-4047 Ext: 100